Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and DMT Consultant Dr. David Nutt DM, FRCP, FRCPSYCH, FSB, FMEDSCI will be discussing the Company’s DMT Stroke Clinical Research Program on an upcoming BioPub webcast.

The BioPub webcast will be held Wednesday March 3, 2021 hosted by Dr. KSS at 1:00 PM EST. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.

BioPub has been analyzing small-cap special situation biotech investments for seven years to readers in over 40 countries.

When: Wednesday March 3, 2021 01:00 PM Eastern Time (US and Canada)

Topic: Algernon Ups the Ante

Guests: Algernon Pharmaceuticals CEO Christopher J. Moreau and DMT consultant Dr. David Nutt, renowned British psychoneuropharmacologist

Please click the link below to join the webinar:
https://us02web.zoom.us/j/85667379852

Or iPhone one-tap : 
    US: [phone],,85667379852#  or [phone],,85667379852# 

Or Telephone:
    Dial(for higher quality, dial a number based on your current location):
        US: [phone]  or [phone]  or [phone]  or [phone]  or [phone]  or [phone]

Webinar ID: 856 6737 9852
    International numbers available: https://us02web.zoom.us/u/km2qxNwyI

About BioPub

BioPub.co is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don't get and presence at meetings others don't bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily.